UY25774A1 - Tabletas de valaciclovir que contienen dioxido de silicio coloidal - Google Patents
Tabletas de valaciclovir que contienen dioxido de silicio coloidalInfo
- Publication number
- UY25774A1 UY25774A1 UY25774A UY25774A UY25774A1 UY 25774 A1 UY25774 A1 UY 25774A1 UY 25774 A UY25774 A UY 25774A UY 25774 A UY25774 A UY 25774A UY 25774 A1 UY25774 A1 UY 25774A1
- Authority
- UY
- Uruguay
- Prior art keywords
- valacyclovir
- tablet
- filler
- silicon dioxide
- lubricant
- Prior art date
Links
- 229940093257 valacyclovir Drugs 0.000 title abstract 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title abstract 4
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 title abstract 4
- 239000000377 silicon dioxide Substances 0.000 title abstract 2
- 235000012239 silicon dioxide Nutrition 0.000 title abstract 2
- 239000000945 filler Substances 0.000 abstract 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 239000000314 lubricant Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract 1
- 239000001569 carbon dioxide Substances 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001050 lubricating effect Effects 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229910052710 silicon Inorganic materials 0.000 abstract 1
- 239000010703 silicon Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9501127.6A GB9501127D0 (en) | 1995-01-20 | 1995-01-20 | Tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25774A1 true UY25774A1 (es) | 2000-10-31 |
Family
ID=10768317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25774A UY25774A1 (es) | 1995-01-20 | 1999-10-28 | Tabletas de valaciclovir que contienen dioxido de silicio coloidal |
| UY25778A UY25778A1 (es) | 1995-01-20 | 1999-10-29 | Proceso para preparar tabletas de valaciclovir que contiene dioxido de silicio coloidal |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25778A UY25778A1 (es) | 1995-01-20 | 1999-10-29 | Proceso para preparar tabletas de valaciclovir que contiene dioxido de silicio coloidal |
Country Status (38)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| CA2243237C (en) * | 1996-01-19 | 2008-09-02 | Glaxo Group Limited | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application |
| AR017512A1 (es) * | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas |
| AR016827A1 (es) | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| BR9916361A (pt) * | 1998-12-18 | 2002-11-05 | Abbott Lab | Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia |
| GB0010446D0 (en) * | 2000-04-28 | 2000-06-14 | Glaxo Wellcome Kk | Pharmaceutical formulation |
| UA75135C2 (en) * | 2001-05-01 | 2006-03-15 | Pfizer Prod Inc | Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions |
| US7815936B2 (en) * | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| AU2002348022B2 (en) * | 2001-11-05 | 2006-06-15 | Glaxo Group Limited | Anhydrous crystal form of valaciclovir hydrochloride |
| CA2465928C (en) * | 2001-11-14 | 2010-01-19 | Teva Pharmaceutical Industries Ltd. | Synthesis and purification of valacyclovir |
| GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| EP1517678A2 (en) * | 2002-06-24 | 2005-03-30 | Ranbaxy Laboratories Limited | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
| WO2004035583A1 (en) * | 2002-10-16 | 2004-04-29 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20050059684A1 (en) * | 2002-10-16 | 2005-03-17 | Ben-Zion Dolitzky | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20040109889A1 (en) * | 2002-12-04 | 2004-06-10 | Bunick Frank J. | Surface treatment composition for soft substrates |
| WO2004106338A1 (en) * | 2003-05-30 | 2004-12-09 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. | Novel crystalline forms of valacyclovir hydrochloride |
| EP2014660A3 (en) * | 2003-06-02 | 2009-07-15 | Teva Pharmaceutical Industries Ltd | Novel crystalline forms of valacyclovir hydrochloride |
| US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
| HUE044822T2 (hu) | 2003-09-12 | 2019-11-28 | Amgen Inc | Cinakalcet HCl gyors feloldódású készítménye |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| EP1541133B1 (en) * | 2003-12-09 | 2005-08-10 | Helm AG | Pharmaceutical formulation of valaciclovir |
| US7344907B2 (en) * | 2004-11-19 | 2008-03-18 | International Business Machines Corporation | Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale |
| KR101116747B1 (ko) | 2004-12-06 | 2012-02-22 | 에스케이케미칼주식회사 | 안정성이 개선된 말레인산 암로디핀 약제 조성물 |
| DK1868579T3 (da) | 2005-03-07 | 2011-01-10 | Bayer Schering Pharma Ag | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer |
| ATE546451T1 (de) * | 2005-05-25 | 2012-03-15 | Lilly Co Eli | Cyclopropancarbonsäureester von acyclovir |
| EP1746098A1 (en) * | 2005-07-21 | 2007-01-24 | SOLMAG S.p.A. | Valacyclovir polymorphs and a process for the preparation thereof |
| WO2007090595A1 (en) * | 2006-02-06 | 2007-08-16 | Fidia Pharmaceutici S.P.A. | Solid formulations of valacyclovir hydrochloride |
| JP2009536165A (ja) * | 2006-05-10 | 2009-10-08 | エボニック デグサ ゲーエムベーハー | 医薬組成物におけるロール圧縮された熱分解的に製造された二酸化ケイ素の使用 |
| EP2037887B1 (en) * | 2006-05-31 | 2010-09-15 | Vertex Pharmaceuticals Incorporated | Oral controlled release formulations of an interleukin-1 beta converting enzyme inhibitor |
| US20090291136A1 (en) * | 2006-07-11 | 2009-11-26 | Lek Pharmaceuticals D.D. | Multiple Unit Tablets |
| US20080167325A1 (en) * | 2006-12-27 | 2008-07-10 | Bs Praveen Kumar | Valacyclovir compositions |
| US20090076039A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched valacyclovir |
| ITRM20080027A1 (it) * | 2008-01-18 | 2009-07-19 | Maria Balestrieri | Uso di aciclovir per il trattamento delle condilomatosi. |
| US20100124560A1 (en) * | 2008-11-14 | 2010-05-20 | Mcneil Ab | Multi portion intra-oral dosage form and use thereof |
| DK2407166T3 (da) * | 2009-03-13 | 2013-10-07 | Toyama Chemical Co Ltd | Tablet og granuleret pulver indeholdende 6-fluor-3-hydroxy-2-pyrazin-carboxamid |
| CH703348A1 (de) * | 2010-06-29 | 2011-12-30 | Mepha Gmbh | Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen. |
| GB2515486A (en) * | 2013-06-24 | 2014-12-31 | Kraft Foods R & D Inc | Soluble Beverage Ingredients |
| KR101497508B1 (ko) * | 2013-12-20 | 2015-03-03 | 한국유나이티드제약 주식회사 | 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법 |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| WO2020049536A1 (en) * | 2018-09-07 | 2020-03-12 | Jubilant Generics Limited | Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof |
| CN110279667B (zh) * | 2019-07-30 | 2023-02-10 | 珠海润都制药股份有限公司 | 一种盐酸伐昔洛韦片及其制备方法 |
| EP4157221A4 (en) * | 2020-06-01 | 2024-07-24 | Shilpa Medicare Limited | RAPIDLY DISPERSABLE PHARMACEUTICAL COMPOSITION CONTAINING CAPECITABINE |
| TWI884340B (zh) * | 2020-12-01 | 2025-05-21 | 南韓商Ｌｇ化學股份有限公司 | 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法 |
| CA3266275A1 (en) * | 2022-08-31 | 2024-03-07 | Astrazeneca Ab | PHARMACEUTICAL FORMULATION |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1259924A (en) * | 1985-03-25 | 1989-09-26 | Wallace E. Becker | Pharmaceutical tableting method |
| AP55A (en) * | 1987-08-15 | 1989-09-26 | The Wellcome Foundation Ltd | Therapeutic Acyclic Nucleosides |
| EP0349103B1 (en) * | 1988-05-04 | 1992-11-25 | Smith Kline & French Laboratories Limited | Chewable tablet |
| ATE133068T1 (de) * | 1991-01-30 | 1996-02-15 | Wellcome Found | Wasserlösliche tabletten |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| GB9317146D0 (en) * | 1993-08-18 | 1993-10-06 | Wellcome Found | Therapeutic combinations |
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
-
1995
- 1995-01-20 GB GBGB9501127.6A patent/GB9501127D0/en active Pending
-
1996
- 1996-01-19 JP JP52212696A patent/JP3350055B2/ja not_active Expired - Fee Related
- 1996-01-19 ZA ZA96448A patent/ZA96448B/xx unknown
- 1996-01-19 DK DK96900626T patent/DK0806943T3/da active
- 1996-01-19 CN CNB2003101029136A patent/CN1313081C/zh not_active Expired - Fee Related
- 1996-01-19 AP APAP/P/1997/001057A patent/AP666A/en active
- 1996-01-19 TR TR97/00657T patent/TR199700657T1/xx unknown
- 1996-01-19 DE DE69607146T patent/DE69607146T2/de not_active Expired - Lifetime
- 1996-01-19 MY MYPI96000222A patent/MY126346A/en unknown
- 1996-01-19 GE GEAP19963844A patent/GEP20022752B/en unknown
- 1996-01-19 EE EE9700352A patent/EE03336B1/xx not_active IP Right Cessation
- 1996-01-19 CZ CZ0229297A patent/CZ296514B6/cs not_active IP Right Cessation
- 1996-01-19 CA CA002210891A patent/CA2210891C/en not_active Expired - Fee Related
- 1996-01-19 EA EA199700123A patent/EA000276B1/ru not_active IP Right Cessation
- 1996-01-19 WO PCT/GB1996/000111 patent/WO1996022082A1/en not_active Ceased
- 1996-01-19 PT PT96900626T patent/PT806943E/pt unknown
- 1996-01-19 EP EP96900626A patent/EP0806943B1/en not_active Expired - Lifetime
- 1996-01-19 SK SK964-97A patent/SK282030B6/sk not_active IP Right Cessation
- 1996-01-19 US US08/875,172 patent/US5879706A/en not_active Expired - Lifetime
- 1996-01-19 BR BR9606769A patent/BR9606769A/pt not_active IP Right Cessation
- 1996-01-19 IL IL11683096A patent/IL116830A/xx not_active IP Right Cessation
- 1996-01-19 NZ NZ298846A patent/NZ298846A/en not_active IP Right Cessation
- 1996-01-19 AU AU44534/96A patent/AU710823B2/en not_active Ceased
- 1996-01-19 CN CN96192661A patent/CN1131026C/zh not_active Expired - Fee Related
- 1996-01-19 AT AT96900626T patent/ATE190483T1/de not_active IP Right Cessation
- 1996-01-19 KR KR1019970704915A patent/KR100412298B1/ko not_active Expired - Lifetime
- 1996-01-19 HU HU9801872A patent/HU226131B1/hu not_active IP Right Cessation
- 1996-01-19 RO RO97-01333A patent/RO118175B1/ro unknown
- 1996-01-19 ES ES96900626T patent/ES2145425T3/es not_active Expired - Lifetime
- 1996-01-19 UA UA97084269A patent/UA68325C2/uk unknown
- 1996-01-19 IN IN100MA1996 patent/IN181318B/en unknown
-
1997
- 1997-07-16 OA OA70052A patent/OA10500A/en unknown
- 1997-07-18 PL PL96321361A patent/PL185307B1/pl not_active IP Right Cessation
- 1997-07-18 FI FI973062A patent/FI119722B/fi not_active IP Right Cessation
- 1997-07-18 NO NO19973327A patent/NO311488B1/no not_active IP Right Cessation
- 1997-08-14 BG BG101831A patent/BG63187B1/bg unknown
-
1999
- 1999-10-28 UY UY25774A patent/UY25774A1/es unknown
- 1999-10-29 UY UY25778A patent/UY25778A1/es not_active IP Right Cessation
-
2000
- 2000-06-14 GR GR20000401364T patent/GR3033677T3/el not_active IP Right Cessation
- 2000-08-23 CY CY0000042A patent/CY2182B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25774A1 (es) | Tabletas de valaciclovir que contienen dioxido de silicio coloidal | |
| ES2157929T3 (es) | Beta-d-dioxolano-nucleosidos enantiomeramente puros. | |
| NL980008I1 (nl) | Gebruik van sertindool voor de behandeling van schizofrenie. | |
| AR002270A1 (es) | Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina | |
| UA27748C2 (uk) | Похідні піримідину, що мають активність антагоністів ангіотензину іі, спосіб їх отримання та фармацевтична композиція | |
| ES2139798T3 (es) | Matriz de liberacion controlada para productos farmaceuticos. | |
| HUT62467A (en) | Process for producing locally applicable pharmaceutical compositions comprising allylamine derivative, against fungus infection of nails | |
| ES2083668T5 (es) | Combinaciones antiviricas que contienen analogos de nucleosido. | |
| MX9200361A (es) | Nuevo uso del antagonista de adenosina. | |
| EP0444196A4 (en) | Agent for treatment and prophylaxis of ischemic disease of heart or brain | |
| CZ226195A3 (en) | The use of lamotrigin for preparing medicaments intended for treating neuronal degeneration caused by aids | |
| MX9204394A (es) | Derivados de amida del antibiotico a 40926, procedimiento para su preparacion y composicion farmaceutica que los contienen. | |
| ES2173883T3 (es) | Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion. | |
| HUT52379A (en) | Process for producing ribonucleotide reductase inhibitor, antiviral combinations comprising same, as well as pharmaceutical compositions comprising these combinations as active ingredient | |
| CO4130200A1 (es) | Inhibidores de proteasa del hiv utiles en el tratamiento del sida | |
| FR2701260B1 (fr) | Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments. | |
| MC1930A1 (fr) | Produit antiviral | |
| ES2091941T3 (es) | Potenciador del efecto antineoplasico y agente antineoplasico. | |
| ES2191908T3 (es) | 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido. | |
| AR005551A1 (es) | Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple | |
| IL84096A0 (en) | Therapeutic agent for the treatment of peptic ulcer disease comprising a purine derivative | |
| TR200102009T2 (tr) | Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı | |
| FI945446A0 (fi) | Kotiinin käyttö tupakan vieroitusoireyhtymän lievittämiseksi | |
| ES2049711T1 (es) | Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de la cistinuria. | |
| AR005456A1 (es) | Comprimidos y tabletas farmaceuticas que contienen 2-(2-(2-amino-9h-purin-9-il)etil)-1,3-propanodiol diacetato (famcicloviri) yprocedimiento para obtenerlos |